TOI vs AIOT vs ONCO vs CRVS vs TRAK vs KO vs JPM

For growth investors, The Oncology Institute, Inc.

(TOI) is the stronger pick with 27. 8% revenue growth year-over-year, versus -67. 7% for Onconetix, Inc. (ONCO). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate The Oncology Institute, Inc. (TOI) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus The Coca-Cola Company at 27. 2x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ReposiTrak, Inc. wins at 0. 74x versus The Coca-Cola Company's 2. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Corvus Pharmaceuticals, Inc.

(CRVS) delivered a total return of +321. 6%, compared to -100. 0% for Onconetix, Inc. (ONCO). Over 10 years, the gap is even starker: JPM returned +465. 8% versus ONCO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus PowerFleet, Inc. 's 2. 71β — meaning AIOT is approximately -1451% more volatile than KO relative to the S&P 500. On balance sheet safety, Onconetix, Inc. (ONCO) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), The Oncology Institute, Inc.

(TOI) is pulling ahead at 27. 8% versus -67. 7% for Onconetix, Inc. (ONCO). On earnings-per-share growth, the picture is similar: Onconetix, Inc. grew EPS 99. 1% year-over-year, compared to 1. 5% for JPMorgan Chase & Co.. Over a 3-year CAGR, AIOT leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ReposiTrak, Inc.

(TRAK) is the more profitable company, earning 30. 9% net margin versus -1721. 0% for Onconetix, Inc. — meaning it keeps 30. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -778. 2% for ONCO. At the gross margin level — before operating expenses — TRAK leads at 83. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, ReposiTrak, Inc. (TRAK) is the more undervalued stock at a PEG of 0. 74x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 25. 4x for ReposiTrak, Inc. — 11. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CRVS: 178. 0% to $33. 17.

In this comparison, AIOT (17.

8% yield), KO (2. 5% yield), JPM (1. 9% yield), TRAK (0. 9% yield) pay a dividend. TOI, ONCO, CRVS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Corvus Pharmaceuticals, Inc. (CRVS) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, CRVS: -6. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (TOI (Healthcare) and AIOT (Technology) and ONCO (Healthcare) and CRVS (Healthcare) and TRAK (Technology) and KO (Consumer Defensive) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: TOI is a small-cap high-growth stock; AIOT is a small-cap income-oriented stock; ONCO is a small-cap quality compounder stock; CRVS is a small-cap quality compounder stock; TRAK is a small-cap quality compounder stock; KO is a large-cap quality compounder stock; JPM is a large-cap deep-value stock. AIOT, TRAK, KO, JPM pay a dividend while TOI, ONCO, CRVS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.